Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612126 | 0.89 | CNR1 (0.56) | NAMPTLMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3605877 | 0.87 | ALDH1A1 (0.49) | NAMPTLMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL3476368 | 0.85 | NAMPT (0.54) | NAMPTMAPTALDH1A1KMT2A | |
| SCHEMBL3603153 | 0.85 | LMNA (0.44) | NAMPTLMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL3602176 | 0.84 | LMNA (0.43) | NAMPTLMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL3596925 | 0.84 | NPC1 (0.52) | LMNAMAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3617333 | 0.84 | LMNA (0.43) | NAMPTLMNAMAPTTDP1ALDH1A1 | |
| SCHEMBL3607440 | 0.83 | HSD17B10 (0.47) | LMNAMAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3620990 | 0.83 | LMNA (0.43) | LMNAMAPTTDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3603163 | 0.83 | LMNA (0.43) | NAMPTLMNAMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | claimed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK & CO., INC. (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222322-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | IDO1, IDO2, INMT | NAMPT 45/4885LMNA 3908/4885MAPT 716/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | NAMPT 1159/4885LMNA 4668/4885MAPT 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.